Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CELU Stock Forecast 2026-2027
$0.77
Current Price
$22.58M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CELU Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CELU Price Momentum
+4.1%
1 Week Change
-3.8%
1 Month Change
-65.0%
1 Year Change
-30.6%
Year-to-Date Change
-82.3%
From 52W High of $4.35
+37.2%
From 52W Low of $0.56
📊 TOP ANALYST CALLS
Did CELU Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Celularity is one of their latest high-conviction picks.
Latest CELU Stock Price Targets & Analyst Predictions
CELU has shown a year-to-date change of -30.6% and a 1-year change of -65.0%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CELU. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CELU Analyst Ratings
0
Buy
0
Hold
0
Sell
CELU Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.77
Latest CELU Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CELU.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 9, 2025 | WBB Securities | Steve Brozak | Buy | Upgrade | $6.00 |
| Aug 18, 2025 | WBB Securities | Speculative Buy | Initiates | $N/A | |
| Jan 30, 2023 | Morgan Stanley | Jeffrey Hung | Underweight | Downgrade | $1.00 |
| Jan 30, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $2.50 |
| Dec 22, 2022 | Oppenheimer | Matthew Biegler | Perform | Downgrade | $N/A |
| Sep 12, 2022 | Morgan Stanley | Jeffrey Hung | Equal-Weight | Maintains | $5.00 |
| Aug 25, 2022 | Alliance Global Partners | James Molloy | Buy | Initiates | $15.00 |
| Aug 23, 2022 | Truist Securities | Asthika Goonewardene | Hold | Maintains | $6.00 |
| Jun 22, 2022 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Apr 6, 2022 | Truist Securities | Hold | Downgrade | $N/A | |
| Jan 28, 2022 | Oppenheimer | Outperform | Initiates | $N/A | |
| Nov 24, 2021 | Morgan Stanley | Equal-Weight | Initiates | $N/A | |
| Oct 19, 2021 | Truist Securities | Buy | Initiates | $N/A |
Celularity Inc. (CELU) Competitors
The following stocks are similar to Celularity based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Celularity Inc. (CELU) Financial Data
Celularity Inc. has a market capitalization of $22.58M with a P/E ratio of 2.3x. The company generates $26.55M in trailing twelve-month revenue with a 24.4% profit margin.
Revenue growth is -77.4% quarter-over-quarter, while maintaining an operating margin of -492.2% and return on equity of +241.2%.
Valuation Metrics
Market Cap
$22.58M
Enterprise Value
$90.69M
P/E Ratio
2.3x
PEG Ratio
-1.4x
Price/Sales
0.9x
Growth & Margins
Revenue Growth (YoY)
-77.4%
Gross Margin
-79.7%
Operating Margin
-492.2%
Net Margin
+24.4%
EPS Growth
-77.4%
Financial Health
Cash/Price Ratio
+27.7%
Current Ratio
0.2x
Debt/Equity
-2.0x
ROE
+241.2%
ROA
-30.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Celularity Inc. (CELU) Business Model
About Celularity Inc.
What They Do
Develops placental-derived cell therapies for diseases.
Business Model
Celularity Inc. focuses on creating off-the-shelf allogeneic cell therapies derived from postpartum placental cells. The company generates revenue through the development and commercialization of these innovative cellular products aimed at treating cancer, immuno-oncology, infectious diseases, and degenerative conditions, addressing significant unmet medical needs.
Additional Information
The company utilizes a proprietary technology platform to enhance immune responses with its therapies, positioning itself at the forefront of cell therapy advancements. This strategic focus not only meets the growing demand for transformative medical treatments but also enhances Celularity's value within the biopharmaceutical market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
115
CEO
Dr. Robert Joseph Hariri M.D., Ph.D.
Country
United States
IPO Year
2021
Website
www.celularity.comCelularity Inc. (CELU) Latest News & Analysis
Latest News
Quick Summary
The news excerpt notes locations in Florham Park, N.J., and Orlando, Fla., but lacks specific information relevant to investors. No actionable insights are provided.
Why It Matters
The locations suggest potential developments or partnerships between companies in these regions, which may impact local economies and investor sentiments related to those businesses.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Celularity Releases CEO Letter to Shareholders
1 month ago
Quick Summary
Celularity Inc. has published a Letter to Shareholders from CEO Robert J. Hariri on its website, detailing company updates for investors.
Why It Matters
Celularity's shareholder letter may signal strategic updates or financial performance insights, impacting investor sentiment and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Celularity Inc. has appointed Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. The company focuses on placental-derived cellular therapies.
Why It Matters
Rick Gonzalez's appointment as CCO may signal a strategic shift in Celularity's commercial approach, potentially impacting revenue growth and market positioning in regenerative medicine.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Celularity Inc. (Nasdaq: CELU) received a notification from Nasdaq for non-compliance due to a delayed filing of its Q1 2026 report, violating Listing Rule 5250(c)(1).
Why It Matters
Celularity Inc.'s non-compliance with Nasdaq filing requirements may lead to delisting, impacting share price and investor confidence in the company's financial stability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
2 months ago
Quick Summary
The company is implementing a focused strategy to enhance its balance sheet and position itself for long-term growth.
Why It Matters
A focused strategy and strengthened balance sheet indicate improved financial health and potential for sustainable growth, which can enhance investor confidence and drive stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NEXGEL, Inc. has appointed Ian Blackman as Chief Financial Officer to oversee the integration of the Celularity acquisition and drive business growth. The company specializes in hydrogel products.
Why It Matters
The appointment of Ian Blackman as CFO signals a strategic move to enhance financial management and drive growth post-acquisition, potentially boosting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CELU Stock
What is Celularity Inc.'s (CELU) stock forecast for 2027?
Analyst forecasts for Celularity Inc. (CELU) are not currently available. The stock is trading at $0.77.
Is CELU stock a good investment in 2027?
Analyst ratings for CELU are not currently available. The stock is currently trading at $0.77. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CELU stock?
Price predictions from Wall Street analysts for CELU are not currently available. The stock is trading at $0.77.
What is Celularity Inc.'s business model?
Celularity Inc. focuses on creating off-the-shelf allogeneic cell therapies derived from postpartum placental cells. The company generates revenue through the development and commercialization of these innovative cellular products aimed at treating cancer, immuno-oncology, infectious diseases, and degenerative conditions, addressing significant unmet medical needs.
What is the highest forecasted price for CELU Celularity Inc.?
Price targets from Wall Street analysts for CELU are not currently available. The stock is trading at $0.77.
What is the lowest forecasted price for CELU Celularity Inc.?
Price targets from Wall Street analysts for CELU are not currently available. The stock is trading at $0.77.
What is the overall CELU consensus from analysts for Celularity Inc.?
Analyst ratings for CELU are not currently available. The stock is trading at $0.77.
How accurate are CELU stock price projections?
Stock price projections, including those for Celularity Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:16 AM UTC